GRAIL Consensus Price Target Increased by 32.52% to $99.35
The average one-year price target for GRAIL (NASDAQGS:GRAL) (BMV:GRAL) has been revised to $99.35 / share. This is an increase of 32.52% from the prior estimate of $74.97 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $60.60 to a high of $157.50 / share. The average price target represents a decrease of 25.05% from the latest reported closing price of $132.56 / share, as of October 1, 2026. This target range has widened, with the current target range width at $96.90 compared to the prior width of $31.80, representing a target range width change percent of +204.72%.
The consensus target has experienced a consecutive target revision direction of increased for 4 times. Looking at the target history, the mean target was $69.76 on August 4, 2026, rising to $73.82 on August 28, 2026, then to $74.97 on September 15, 2026, and reaching $99.35 on October 2, 2026. This represents a target change since the 90-day baseline date of June 30, 2026, of +51.56%. For comparison, the observed twelve-month high mean target was $107.10 on February 3, 2026, and the observed twelve-month low mean target was $62.73 on November 9, 2025.
In terms of price performance, the stock experienced a price change of +5.87% over one week, from a baseline close of $125.21 on September 24, 2026. Over one month, the price change was +66.14% from a baseline close of $79.79 on September 1, 2026. In its latest earnings report on August 5, 2026, the company reported an actual EPS of -2.56, compared to the estimated EPS of -2.7053. Actual revenue was $44,687,000.00, which was a +2.46% surprise over the estimated revenue of $43,615,587.00.
Recent analyst actions include Guggenheim maintaining a Buy rating on October 1, 2026, and Canaccord Genuity maintaining a Buy rating on September 28, 2026. Mizuho maintained a Neutral rating on September 25, 2026, and Baird maintained an Outperform rating on September 22, 2026. As of September 1, 2026, the recommendation breakdown consisted of 4 strong buy, 5 buy, and 6 hold recommendations, representing a positive recommendation percentage of 60.0% and a hold percentage of 40.0%. This distribution was unchanged from the prior period as of August 1, 2026.
Within the Construction & Engineering sub-industry, which covers 29 companies, 7 companies have raised targets, 13 have lowered, and 9 remain unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +71.39%. Among its peers, Guardant Health and Natera both saw upward target revisions, while NeoGenomics remained unchanged.
| Company | Target revision | Implied change |
|---|---|---|
| Guardant Health | +1.33% | +12.38% |
| Natera | +3.01% | -15.14% |
| NeoGenomics | 0.00% | +13.14% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.